BioAge Labs Company Insiders

BIOA Stock   20.69  2.84  15.91%   
BioAge Labs' insiders are aggressively buying. The analysis of insiders' sentiment of trading BioAge Labs stock suggests that vertually all insiders are extremely bullish at this time. BioAge Labs employs about 62 people. The company is managed by 14 executives with a total tenure of roughly 145 years, averaging almost 10.0 years of service per executive, having 4.43 employees per reported executive.

Insider Sentiment 100

 Aggressively Buying

 
Selling
 
Buying

Latest Trades

2024-10-03Vijay Satyanand PandeAcquired 25306 @ 19.9View
2024-10-01Vijay Satyanand PandeAcquired 126793 @ 19.73View
2024-09-27Vijay Satyanand PandeAcquired 900000 @ 18View
Monitoring BioAge Labs' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioAge Labs. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade BioAge Stock refer to our How to Trade BioAge Stock guide.

BioAge Labs Management Team Effectiveness

The company has return on total asset (ROA) of (0.1746) % which means that it has lost $0.1746 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2564) %, meaning that it created substantial loss on money invested by shareholders. BioAge Labs' management efficiency ratios could be used to measure how well BioAge Labs manages its routine affairs as well as how well it operates its assets and liabilities. As of January 13, 2026, Return On Tangible Assets is expected to decline to -0.19. In addition to that, Return On Capital Employed is expected to decline to -0.22. At present, BioAge Labs' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 3 M, whereas Non Current Assets Total are forecasted to decline to about 967 K.
The current year's Common Stock Shares Outstanding is expected to grow to about 18.6 M
BioAge Labs holds a total of 35.86 Million outstanding shares. Over half of BioAge Labs' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
 
Shares in Circulation  
First Issued
2013-03-31
Previous Quarter
35.9 M
Current Value
35.9 M
Avarage Shares Outstanding
26.1 M
Quarterly Volatility
11.3 M
 
Yuan Drop
 
Covid
Some institutional investors establish a significant position in stocks such as BioAge Labs in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of BioAge Labs, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

BioAge Labs Workforce Comparison

BioAge Labs is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 25,695. BioAge Labs adds roughly 62.0 in number of employees claiming only tiny portion of equities under Health Care industry.

BioAge Labs Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific BioAge Labs insiders, such as employees or executives, is commonly permitted as long as it does not rely on BioAge Labs' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, BioAge Labs insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2025-12-01
0.5
2
4
 86,897 
 173,794 
2017-06-01
7.0
7
1
 405,000 
 0.00 
2016-03-01
5.0
5
1
 406,000 
 200,000 
2015-12-01
0.5
1
2
 154,700 
 181,978 
2015-09-01
2.0
4
2
 46,200 
 20,000 
2014-12-01
2.3333
7
3
 365,000 
 108,083 

BioAge Labs Notable Stakeholders

A BioAge Labs stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as BioAge Labs often face trade-offs trying to please all of them. BioAge Labs' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting BioAge Labs' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Kristen FortneyCEO, CoFounderProfile
Eric MDCOO CoFounderProfile
Rusty MontgomerySenior ResearchProfile
Julie GammelgardSenior PeopleProfile
MD MBAChief OfficerProfile
Justin ReboSenior BiologyProfile
Patrick MDSenior ScienceProfile
Paul MDChief ResearchProfile
Peng MBAChief AgingProfile
Ann BSNChief OfficerProfile
MBA MBAChief AgingProfile
BJ SullivanChief OfficerProfile
Ralph ScarboroughVice AccountingProfile
CarrieLynn FurrSenior AffairsProfile
String symbol = request.getParameter("s");

About BioAge Labs Management Performance

The success or failure of an entity such as BioAge Labs often depends on how effective the management is. BioAge Labs management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of BioAge management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the BioAge management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.18)(0.19)
Return On Capital Employed(0.21)(0.22)
Return On Assets(0.18)(0.19)
Return On Equity(0.25)(0.24)
Please note, the presentation of BioAge Labs' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, BioAge Labs' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of BioAge Labs' management manipulating its earnings.

BioAge Labs Workforce Analysis

Traditionally, organizations such as BioAge Labs use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare BioAge Labs within its industry.

BioAge Labs Manpower Efficiency

Return on BioAge Labs Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee1.1M
Net Loss Per Executive5.1M
Working Capital Per Employee5.3M
Working Capital Per Executive23.5M

Complementary Tools for BioAge Stock analysis

When running BioAge Labs' price analysis, check to measure BioAge Labs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAge Labs is operating at the current time. Most of BioAge Labs' value examination focuses on studying past and present price action to predict the probability of BioAge Labs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAge Labs' price. Additionally, you may evaluate how the addition of BioAge Labs to your portfolios can decrease your overall portfolio volatility.
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.